- Home
- VSTM vs RLAY Comparison
VSTM vs RLAY Comparison
Compare VSTM & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- RLAY
- Stock Information
- Founded
- VSTM 2010
- RLAY 2015
- Country
- VSTM United States
- RLAY United States
- Employees
- VSTM N/A
- RLAY N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VSTM Health Care
- RLAY Health Care
- Exchange
- VSTM Nasdaq
- RLAY Nasdaq
- Market Cap
- VSTM 425.9M
- RLAY 490.3M
- IPO Year
- VSTM 2012
- RLAY 2020
- Fundamental
- Price
- VSTM $4.93
- RLAY $3.18
- Analyst Decision
- VSTM Strong Buy
- RLAY Strong Buy
- Analyst Count
- VSTM 8
- RLAY 11
- Target Price
- VSTM $12.71
- RLAY $18.40
- AVG Volume (30 Days)
- VSTM 2.6M
- RLAY 1.6M
- Earning Date
- VSTM 08-07-2025
- RLAY 08-05-2025
- Dividend Yield
- VSTM N/A
- RLAY N/A
- EPS Growth
- VSTM N/A
- RLAY N/A
- EPS
- VSTM N/A
- RLAY N/A
- Revenue
- VSTM $10,000,000.00
- RLAY $7,679,000.00
- Revenue This Year
- VSTM $129.06
- RLAY $14.31
- Revenue Next Year
- VSTM $306.32
- RLAY N/A
- P/E Ratio
- VSTM N/A
- RLAY N/A
- Revenue Growth
- VSTM N/A
- RLAY N/A
- 52 Week Low
- VSTM $2.10
- RLAY $1.78
- 52 Week High
- VSTM $9.10
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- VSTM 30.80
- RLAY 55.48
- Support Level
- VSTM $5.73
- RLAY $2.98
- Resistance Level
- VSTM $6.62
- RLAY $3.48
- Average True Range (ATR)
- VSTM 0.46
- RLAY 0.25
- MACD
- VSTM -0.17
- RLAY -0.00
- Stochastic Oscillator
- VSTM 0.84
- RLAY 58.45
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).